H3122 cell line

Eleven human lung adenocarcinoma cell lines (EGFR-mutated: HCC827, H1650, and H1975; KRAS-mutated: A549, H2009, and H358; ALK translocation bearer: H3122 and H2228; and Triple Negative (TN) referring to the absence of alterations in EGFR, KRAS, and ALK: CALU3, H1437, and H1781) were used for this study. All cell lines were obtained from the American Type Culture Collection (ATCC), with the exception of the H3122 cell line, which was kindly provided by Dr. Koivunen. Cells were cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA), with the exception of the A549 cell line, which was propagated in DMEM medium (Sigma-Aldrich, St. Louis, MO, USA). Both media were supplemented with 10% fetal bovine serum (FBS, TICO Europe), 1% antibiotic-antimycotic solution (Sigma-Aldrich, St. Louis, MO, USA), and 1% glutamine (v/v). All cell lines were cultured as monolayers at 37 °C and 5% CO₂ in a humidified incubator. Cells were authenticated and periodically checked to ensure the absence of mycoplasm.

The H2228 cell line was obtained from the American Type Culture Collection (Rockville, MD), and the H3122 cell line was a gift from Adi F. Gazdar (UT Southwestern, Dallas, TX). Cells were cultured in 10% fetal bovine serum (FBS), 100-U/mL penicillin, and 100-mg/mL streptomycin (Invitrogen, Carlsbad, CA) at 37°C in an atmosphere with 5% CO₂. Crizotinib, TAE684, ceritinib, alectinib, gefitinib, afatinib, PHA 665752, and AUY922 were purchased from Selleck Chemicals (Houston, TX). EGF and IGF-1 were purchased from Calbiochem and Sigma–Aldrich (St. Louis, MO), respectively. BI 836845 was kindly provided by Boehringer Ingelheim (Vienna, Austria).